The effect of serum on mPr3 and CD177 expression on neutrophils

Amina Bshaena; Salima  Abdulla; Brad  Spiller

doi:10.54361/

Authors

Amina Bshaena National Medical Research Centre, Zawia, Libya Author
Salima Abdulla Cardif Universty U.K Author
Brad Spiller Cardif Universty U.K Author

DOI:

https://doi.org/10.54361/

Keywords:

Proteinase 3, CD177, neutrophils, ANCA-associated vasculitis

Abstract

Proteinase 3 (Pr3) is a serine protease that is stored primarily in azurophilic granules and secretory vesicles in neutrophils. The high affinity Pr3 receptor, CD177, is expressed on a subset of neutrophils (ranging from 0-100%), but usually only half of the circulating neutrophils express CD177 in most normal individuals. As a serine proteinase, Pr3 is controlled by a variety of inhibitors, including alpha-1-antitripsin (AAT). We investigated if the surface expression of Pr3 and CD177 was affected by stimulation of neutrophils in the presence or absence of serum. Methods: Neutrophil cells were isolated from healthy donors. The cells counted and stimulated with fMLP only or cytochalasin B followed by addition of fMLP, and compared to unstimulated controls, in the presence or absence of 100 % autologous serum. The expression of Pr3 and CD177 was analysed by flow cytometery. Results: The expression of membrane bound Pr3 (mPr3) by neutrophils was still detectable in the presence of serum however, the expression was reduced on both mPr3low and mPr3high cells in comparison to cells incubated in the absence of serum. No significant increase was observed in mPr3 expression following stimulation with fMLP in either the presence or absence of serum. In comparison, stimulation with cytochalasin B combined with fMLP resulted in a 9-fold increase (P<0.0001) in the Pr3high cells compared with unstimulated cells in the absence of serum. This increase was only 3-fold (P< 0.002) in the presence of serum. Conclusion: Despite the ability of purified AAT to inhibit Pr3 binding to CD177, significant surface Pr3 was still found on the surface of CD177-positive neutrophils when stimulated in the presence of 100% autologous serum, but only following maximal stimulation of neutrophils.

References

Van der Geld YM, Limburg PC, Kallenberg CG (2001). Proteinase 3, Wegener’s autoantigen: from gene to antigen. J Leuk Biol. 69:177-90.

Bories D, Raynal MC, Solomon DH, Darzynkiewicz Z, Cayre YE (1989). Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 59: 959-68.

Labbaye C, Musette P, Cayre YE (1991). Wegener autoantigen and myeloblastin are encoded by a single mRNA. Proc Natl Acad Sci USA 88: 9253-6.

Witko-Sarsat V, Cramer EM, Hieblot C, Guichard J, Nusbaum P, Lopez S, Lesavre P, Halbwachs-Mecarelli L.(1999). Presence of proteinase 3 in secretory vesicles: evidence of a novel, highly mobilizable intracellular pool distinct from azurophil granules. Blood 94: 2487–96.

Goldmann WH, Niles JL, Arnaout MA (1999). Interaction of purified human proteinase 3 (PR3) with reconstituted lipid bilayers. Eur J Biochem. 261: 155-62.

Fregonese L, Stolk J (2008). Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis. 3:16.

Muller Kobold AC, Kallenberg CG, Tervaert JW (1998). Leucocyte membrane expression of proteinase 3 correlates with disease activity in patients with Wegener's granulomatosis. Br J Rheumatol. 37: 901- 7

Rooney CP, Taggart C, Coakley R, McElvaney NG, O'Neill SJ (2001). Anti-proteinase 3 antibody activation of neutrophils can be inhibited by alpha1-antitrypsin. Am J Respir Cell Mol Biol. 24: 747-54.

Korkmaz B, Kuhl A, Bayat B, Santoso S, Jenne DE (2008). A hydrophobic patch on proteinase 3, the target of autoantibodies in Wegener granulomatosis, mediates membrane binding via NB1 receptors. J Biol Chem. 283: 35976-82.

Korkmaz B., Attucci S., Jourdan M. L., Juliano L., Gauthier F (2005). Inhibition of neutrophil elastase by alpha1-protease inhibitor at the surface of human polymorphonuclear neutrophils. J Immunol. 175: 3329–38

Attucci S., Gauthier A., Korkmaz B., Delépine P., Martino M. F., Saudubray F., Diot P., Gauthier F (2006). EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis. J Pharmacol. Exp Ther. 318: 803–809

Korkmaz B, Jaillet J, Jourdan ML, Gauthier A, Gauthier F, Attucci S (2009). Catalytic activity and inhibition of wegener antigen proteinase 3 on the cell surface of human polymorphonuclear neutrophils. J Biol Chem. 284: 19896-902.

Bauer S, Abdgawad M, Gunnarsson L, Segelmark M, Tapper H, Hellmark T (2007). Proteinase 3 and CD177 are expressed on the plasma membrane of the same subset of neutrophils. J Leukoc Biol. 81: 458-64.

Brachemi S, Mambole A, Fakhouri F, Mouthon L, Guillevin L, Lesavre P, Halbwachs- Mecarelli L (2007). Increased membrane expression of proteinase 3 during neutrophil adhesion in the presence of antiproteinase 3 antibodies. J Am Soc Nephrol. 18: 2330-9.

von Vietinghoff S, Tunnemann G, Eulenberg C, Wellner M, Cristina Cardoso M, Luft FC, Kettritz R (2007). NB1 mediates surface expression of the ANCA antigen proteinase 3 on human neutrophils. Blood 109: 4487-93.

Hu N, Westra J, Kallenberg CG (2009). Membrane-bound proteinase 3 and its receptors: relevance for the pathogenesis of Wegener's Granulomatosis. Autoimmun Rev. 8: 510-4.

Halbwachs-Mecarelli L, Bessou G, Lesavre P, Lopez S, Witko-Sarsat V (1995). Bimodal distribution of proteinase 3 (PR3) surface expression reflects a constitutive heterogeneity in the polymorphonuclear neutrophil pool. FEBS Lett. 374: 29–33.

Schreiber A, Busjahn A, Luft FC, Kettritz R (2003). Membrane expression of proteinase 3 is genetically determined. J Am Soc Nephrol. 14: 68–75.

Yang JJ, Tuttle RH, Hogan SL, Taylor JG, Phillips BD, Falk RJ, Jennette JC (2000) Target antigens for anti-neutrophil cytoplasmic autoantibodies (ANCA) are on the surface of primed and apoptotic but notunstimulated neutrophils. Clin Exp Immunol. 121: 165–72.

Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL (1994). Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol. 95: 244-50.

Hellmich B, Csernok E, Trabandt A, Gross WL, Ernst M (2000). Granulocyte- macrophage colonystimulating factor (GM-CSF) but not granulocyte colony-stimulating factor (G-CSF) induces plasma membrane expression of proteinase 3 (PR3) on neutrophils in vitro. Clin Exp Immunol. 120: 392-8.

Drewniak A, Boelens JJ, Vrielink H, Tool AT, Bruin MC, van den Heuvel-Eibrink M, Ball L, van de Wetering MD, Roos D, Kuijpers TW (2008). Granulocyte concentrates: prolonged functional capacity during storage in the presence of phenotypic changes. Haematologica 93: 1058-67.

Goldschmeding R, van Dalen CM, Faber N, Calafat J, Huizinga TWJ, van der Schoot CE, Clement LT, von dem Borne AEG Kr (1992). Further characterization of the NB1 antigen as a variably expressed 56–62 kD GPI linked glycoprotein of plasma membranes and specific granules of neutrophils. Br J Haematol. 81: 336-45.

Witko-Sarsat V, Reuter N, Mouthon L (2010). Interaction of proteinase 3 with its associated partners: implications in the pathogenesis of Wegener's granulomatosis. Curr Opin Rheumatol. 22: 1-7.

Choi M, Eulenberg C, Rolle S, von Kries JP, Luft FC, Kettritz R (2010). The use of small molecule high-throughput screening to identify inhibitors of the proteinase 3-NB1 interaction. Clin Exp Immunol. 161: 389-96.